InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,301.83
(
1.05%
)
US TECH 100
18,107.40
(
1.51%
)
Dow Jones
39,833.96
(
0.70%
)
Brent Oil
82.56
(
0.01%
)
Bitcoin
65,333.41
(
6.16%
)
Post# of 251825
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: oc631 post# 156451

Tuesday, 02/05/2013 10:58:35 AM

Tuesday, February 05, 2013 10:58:35 AM

Post# of 251825

The Sofosbuvir/Daclatasvir oral combo demonstrated 100% SVR24 rates in GT2/GT3 patients (Phase 2 / n=14).

Note that in that phase II of sofosbuvir + daclatasvir w/wo ribavirin treatment duration was 24 weeks in GT2/3 and perhaps there were other differences like cirrhotic patients.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up